|
Incidence of local and systemic reactions reported for the two vaccine groups |
|||
| Sub/MF59™ %(n) |
Subunit %(n) |
||
|
|
|||
| Local reaction |
Rash |
0.0(0) |
0.5(1) |
| Erythema |
1.5(6) |
1.5(3) |
|
| Induration |
0.5(2) |
2.5(5)* |
|
| Swelling |
2.8(11) |
1.0(2) |
|
| Pain |
10.2(40)** |
3.0(6) |
|
| Pruritus |
1.3(5) |
3.0(6) |
|
| Systemic reaction |
Headache |
3.6(14) |
2.5(5) |
| Fever |
15.9(62)** |
7.6(15) |
|
| Tiredness |
3.3(13) |
1.0(2) |
|
| Diarrhoea |
0.8(3) |
2.0(4) |
|
| Vomiting |
1.0(4) |
1.0(2) |
|
| Myalgia |
1.8(7) |
0.5(1) |
|
| Cough |
2.0(8) |
2.0(4) |
|
| Angina |
1.5(6) |
1.0(2) |
|
| Watery nasal discharge |
1.0(4) |
1.0(2) |
|
| Skin disease (e.g. eczema) |
0.0(0) |
1.0(2) |
|
| Irritability |
0.0(0) |
0.5(1) |
|
|
*P < 0.05 versus the Sub/MF59™ vaccine group; **P ≤ 0.005 versus the Subunit vaccine group Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine | |||
Li et al. Immunity & Ageing 2008 5:2 doi:10.1186/1742-4933-5-2 |
|||